Lutris Pharma Phase 1 Results of LUT014 for Skin Toxicities Associated with Treatment of Colorectal Cancer Patients with EGFR Inhibitors Published in Cancer Discovery
USA - English
LUT014 was found to be safe and effective
LUT014 Phase 2 trial designed to include 117 patients in 20 centers in the US and Israel has been initiated
News provided by
Share this article
Share this article
TEL AVIV, Israel, April 28, 2021 /PRNewswire/ Lutris Pharma, a clinical stage biopharmaceutical company focusing on improving anti-cancer therapies by reducing dose limiting side effects, announced today that results of a Phase1 study for its lead product, LUT014, assessing the safety, tolerability, and efficacy of topically administered LUT014 for the treatment of epidermal growth factor receptor (EGFR) inhibitor-induced acneiform lesions in metastatic colorectal cancer patients, were published in
Lutris Pharma Phase 1 Results of LUT014 for Skin Toxicities Associated with Treatment of Colorectal Cancer Patients with EGFR Inhibitors Published in Cancer Discovery prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.